Tafazzin Antibody (F-7): sc-365810

Tafazzin Antibody (F-7) is a mouse monoclonal IgG2b kappa light chain antibody that detects Tafazzin protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-Tafazzin antibody (F-7) is available in both non-conjugated and various conjugated forms, including agarose, phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Tafazzin (F-7) antibody targets a protein crucial for mitochondrial function, particularly in cardiac and skeletal muscle, where Tafazzin is involved in remodeling mitochondrial membranes and regulating cardiolipin metabolism. Cardiolipin maintains mitochondrial integrity and function, and dysregulation can lead to impaired energy production and increased oxidative stress, contributing to various cardiac diseases. Mutations in Tafazzin have been linked to several serious conditions, including dilated cardiomyopathy, hypertrophic cardiomyopathy, endocardial fibroelastosis, left ventricular noncompaction, and Barth syndrome, a genetic disorder characterized by neutropenia, cardiac and skeletal myopathy, and growth deficiencies. Diverse isoforms of Tafazzin, including membrane-anchored and cytoplasmic variants, underscore the complexity of function and importance in mitochondrial health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Tafazzin Antibody (F-7) References:

1. Phospholipid abnormalities in children with Barth syndrome.  |  Schlame, M., et al. 2003. J Am Coll Cardiol. 42: 1994-9. PMID: 14662265
2. Complex expression pattern of the Barth syndrome gene product tafazzin in human cell lines and murine tissues.  |  Lu, B., et al. 2004. Biochem Cell Biol. 82: 569-76. PMID: 15499385
3. Ypr140wp, 'the yeast tafazzin', displays a mitochondrial lysophosphatidylcholine (lyso-PC) acyltransferase activity related to triacylglycerol and mitochondrial lipid synthesis.  |  Testet, E., et al. 2005. Biochem J. 387: 617-26. PMID: 15588229
4. Characterization of lymphoblast mitochondria from patients with Barth syndrome.  |  Xu, Y., et al. 2005. Lab Invest. 85: 823-30. PMID: 15806137
5. Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome.  |  Brandner, K., et al. 2005. Mol Biol Cell. 16: 5202-14. PMID: 16135531
6. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes.  |  He, Q., et al. 2014. Oxid Med Cell Longev. 2014: 654198. PMID: 25247053
7. Suppression of Tafazzin promotes thyroid cancer apoptosis via activating the JNK signaling pathway and enhancing INF2-mediated mitochondrial fission.  |  Li, X., et al. 2019. J Cell Physiol. 234: 16238-16251. PMID: 30741413
8. Tafazzin deficiency impairs mitochondrial metabolism and function of lipopolysaccharide activated B lymphocytes in mice.  |  Zegallai, HM., et al. 2021. FASEB J. 35: e22023. PMID: 34767647
9. Genetic modifiers modulate phenotypic expression of tafazzin deficiency in a mouse model of Barth syndrome.  |  Wang, S., et al. 2023. Hum Mol Genet. 32: 2055-2067. PMID: 36917259
10. Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer.  |  Li, X., et al. 2024. Cancer Gene Ther. 31: 69-81. PMID: 37935981
11. Cell-Penetrating Peptide Enhances Tafazzin Gene Therapy in Mouse Model of Barth Syndrome.  |  Raghav, R., et al. 2024. Int J Mol Sci. 25: PMID: 39769321

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Tafazzin Antibody (F-7) has 8 citations in a variety of scientific publications.

Primary antibodies like Anti-Tafazzin Antibody (F-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Tafazzin Antibody (F-7) Specifications

Alternate Product Name: Tafazzin

Product Clone Name: F-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids:

Epitope Target: Tafazzin

Epitope Species: human

Product Reactivity/Detection: all isoforms of Tafazzin

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine and bovine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 8 citations in various scientific publications

Available Conjugates/Forms for Tafazzin Antibody (F-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, P: Blocking Peptide, PE: Phycoerythrin